These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34606981)

  • 21. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
    Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
    Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
    J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
    Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
    Yoo HW; Park JY; Kim SG; Jung YK; Lee SH; Kim MY; Jun DW; Jang JY; Lee JW; Kwon OS
    Sci Rep; 2022 Jan; 12(1):193. PubMed ID: 34996920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-invasive assessment of liver fibrosis in patients with hepatitis C: Shear wave elastography and colour Doppler velocity profile technique versus liver biopsy.
    Moustafa EF; Makhlouf N; Hassany SM; Helmy A; Nasr A; Othman M; Seif H; Darwish M; Hassan H; Hessen M
    Arab J Gastroenterol; 2017 Mar; 18(1):6-12. PubMed ID: 28262531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.
    Davidov Y; Kleinbaum Y; Inbar Y; Cohen-Ezra O; Veitsman E; Weiss P; Likhter M; Berdichevski T; Katsherginsky S; Hassid A; Tsaraf K; Silverberg D; Ben Ari Z
    Isr Med Assoc J; 2021 Dec; 23(12):794-800. PubMed ID: 34954919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.
    Persico M; Rosato V; Aglitti A; Precone D; Corrado M; De Luna A; Morisco F; Camera S; Federico A; Dallio M; Claar E; Caporaso N; Masarone M
    Antivir Ther; 2018; 23(2):129-138. PubMed ID: 28799522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
    Akuta N; Toyota J; Karino Y; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; McPhee F; Noviello S; Kumada H
    J Gastroenterol; 2018 Sep; 53(9):1089-1097. PubMed ID: 29500489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncologic Implications of Chronic Hepatitis C Virus Infection.
    Hwang JP; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Torres HA; Bailey HH
    J Oncol Pract; 2019 Dec; 15(12):629-637. PubMed ID: 31825756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    Deuffic-Burban S; Boursier J; Leroy V; Yazdanpanah Y; Castera L; Mathurin P
    J Hepatol; 2017 Feb; 66(2):304-312. PubMed ID: 27743987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
    Lledó GM; Carrasco I; Benítez-Gutiérrez LM; Arias A; Royuela A; Requena S; Cuervas-Mons V; de Mendoza C
    AIDS; 2018 Oct; 32(16):2347-2352. PubMed ID: 30096074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
    D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
    J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrosis reversal after hepatitis C virus elimination.
    Rockey DC
    Curr Opin Gastroenterol; 2019 May; 35(3):137-144. PubMed ID: 30865043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
    Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
    J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced liver disease in Russian children and adolescents with chronic hepatitis C.
    Turkova A; Volynets GV; Crichton S; Skvortsova TA; Panfilova VN; Rogozina NV; Khavkin AI; Tumanova EL; Indolfi G; Thorne C
    J Viral Hepat; 2019 Jul; 26(7):881-892. PubMed ID: 30803105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.